LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p
- 11 May 2021
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 26 (5-6) , 348-360
Abstract
Long non-coding RNAs (lncRNAs) have been reported to participate in regulating gene expression and are related to tumor progression. FGD5 antisense RNA 1 (FGD5-AS1) facilitates the progression of various tumors. However, the expression and function of FGD5-AS1 in ovarian cancer (OC) and its mechanism of action are not yet clear. Real-time polymerase chain reaction (RT-PCR) was employed to explore the expression levels of FGD5-AS1 and miR-142-5p in OC. The relationship between the expression of FGD5-AS1 and clinicopathological indicators of OC patients was analyzed by χ2 test. CCK-8 assay, BrdU assay, and Transwell assay were carried out to detect cell proliferation, migration, as well as invasion, respectively. Subcutaneous tumorigenesis experiment and lung metastasis model were used to examine the biological effects of FGD5-AS1 in OC in vivo. Dual luciferase reporter gene assay or RIP experiment was employed to explore the targeting relationship between FGD5-AS1 and miR-142-5p, as well as miR-142-5p and PD-L1 3′UTR. First, we found that FGD5-AS1 was markedly up-regulated in OC. Moreover, its high expression level was associated with positive local lymph node metastasis and higher T stage in OC patients. Gain-of-function and loss-of-function assays demonstrated that FGD5-AS1 facilitated the proliferation, migration, as well as invasion of OC cells. Mechanistically, it was revealed that FGD5-AS1 targeted miR-142-5p to repress its expression and function. Furthermore, miR-142-5p has a binding site for 3’ UTR of PD-L1, and FGD5-AS1 could positively regulate PD-L1 expression via repressing miR-142-5p. The present study reports that FGD5-AS1/miR-142-5p/PD-L1 axis is involved in regulating OC progression. Graphic abstractKeywords
This publication has 48 references indexed in Scilit:
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancerJournal of Ovarian Research, 2018
- miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathwayOncology Reports, 2018
- Acid- and reduction-sensitive micelles for improving the drug delivery efficacy for pancreatic cancer therapyBiomaterials Science, 2018
- Dual Roles of Protein as a Template and a Sulfur Provider: A General Approach to Metal Sulfides for Efficient Photothermal Therapy of CancerSmall, 2017
- Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer CellsCellular Physiology and Biochemistry, 2017
- LncRNA‐ATB: An indispensable cancer‐related long noncoding RNACell Proliferation, 2017
- miRNAs and ovarian cancer: An overviewJournal of Cellular Physiology, 2017
- miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunityBiochemical and Biophysical Research Communications, 2017
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014